Drug Pricing Investigation By Department Of Justice Requested - Rep. Coburn

The pharmaceutical industry's pricing practices for chemically similar brand name drugs merits federal investigation, Rep. Coburn (R-Okla.) said in a June 15 letter to U.S. Attorney General Reno.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet